Clinical Trials

The purpose of this study is to find out if the size of a donor's remaining kidney or the microscopic appearance of a tissue biopsy from the donated kidney is predictive of long-term kidney function and overall health.

The purpose of this study is to to determine whether or not prior living kidney donors have an increased risk of bone fractures. The study will also determine bone structure and health in prior living donors as compared to matched controls.  

We will determine if living kidney donors are at increased risk of bone disease and fractures following kidney donation. This information will be valuable in informing future kidney donors of the risks of donation and in devising treatments, such as administration of vitamin D analogs like calcitriol, to ...

The purpose of this study is to create a group of blood and urine samples from Mayo Clinic patients being screened for the kidney donor program as well as to collect risk factor data through a questionnaire. The data, blood and urine samples will be used for future research of kidney diseases at Mayo Clinic and future research at Mayo Clinic to learn about, prevent, or treat other health problems.

The purpose of this study is to use urinary exosomes to non-invasively identify (protein biomarkers) various conditions affecting the renal transplant. 

The purpose of this study is to evaluate the utility of using anti-HLA antibody titer to measure the effectiveness of antibody lowering therapy (i.e., desensitization) in highly-sensitized kidney transplant candidates.

The purpose of this study is to attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

The purpose of this study is to attempt to improve outcomes after kidney transplantation and to improve the safety of living kidney donation based upon variation in the apolipoprotein L1 gene (APOL1). Genes control what is inherited from a family, such as eye color or blood type. Variation in APOL1 can cause kidney disease. African Americans, Afro-Caribbeans, Hispanic Blacks, and Africans are more likely to have the APOL1 gene variants that cause kidney disease. APOLLO will test DNA from kidney donors and recipients of kidney transplants for APOL1 to determine effects on kidney transplant-related outcomes.

The purpose of this study will be to evaluate the effect of the US Health Resources and Services Administration (HRSA) program to reimburse lost wages on the decision of individuals to initiate evaluation for living organ donation.

The purpose of this study is to obtain valuable knowledge to rapidly promote the Hispanic Kidney Transplant Program (HKTP) as a novel approach for increasing living donor kidney transplants(LDKT) nationally in the Hispanic community.

The purpose of this study is to compare tacrolimus formulations (Envarsus XR® versus twice a day tacrolimus) with the hypothesis that Envarsus XR® improves transplant- and tacrolimus- associated symptoms when compared to a twice a day tacrolimus regimen.

The purpose of this study is to determine if the Living Donor Assessment Tool (LDAT) is an effective tool to improve the psychosocial evaluation of potential live kidney and liver donors. The LDAT was developed by the living donation team at the Zweig Family Center for Living Donation at the Mount Sinai Recanati/Miller Transplantation Institute. It assesses important areas of the evaluation process such as motivation (reason) for donation, knowledge of living donation, support, relationship to organ recipient, feelings about donation, stability in life and psychiatric and addiction history and provides a score that can be used to measure the ...

The primary purpose of this study is to implement the Hispanic Kidney Transplant Program (HKTP) at two transplant centers by conducting a needs assessment of barriers and using a “learning collaborative” model to deliver HKTP protocols, scripts, and materials.

The purpose of this study is to evaluate post-transplant clinical outcomes in receipients of kidney transplants who are undergoing TruGraf® and TRAC™ monitoring.

The purpose of this study is to create a detailed immune profile of transplant patients and donors to determine what characteristics are associated with response to COVID vaccination.

Transplant recipients and donors who respond to immunization to COVID vaccine will have a different immunologic profile at basline than those who do not repspond.

We woudl like to create a detailed immune profile of Transplant patients and donors to determne what  characteristics are associated with response to the COVID vaccination.

The purpose of this study is to validate the use of an RNA-seq based peripheral blood assay in renal transplant recipients in adult kidney transplant recipients.  

The specific purpose of this study is to compare the characteristics of patients at Mayo Clinic Rochester who received a living donor kidney transplant here preemptively versus those who dialyzed either less than 1 year or more than 1 year. 

The purpose of this study is to analyze the effect of parity, menopause and reproductive lifespan on kidney structure and function.

The purpose of this study is to connect the findings of TruGraf (a peripheral blood RNA signature that has been shown to correlate with rejection in kidney transplants) with rejection episodes in kidney transplant patients that are managed using standard of care clinical protocols at the three Mayo transplant sites. 

The primary objective of this study is to demonstrate the safety and efficacy of cellular immunotherapy with MDR-101 for induction of functional immune tolerance in recipients of human leukocyte antigen (HLA)-matched, living donor kidney transplants.

The purpose of this study is to assess the safety, effectiveness, and overall benefit of FCR001 cell therapy in de novo living donor renal transplantation.

This study will compare the incidence of a two-part composite endpoint consisting of de novo donor specific antibody (DSA) formation or a designation of "immune activation" (IA) on peripheral blood molecular profiling in patients maintained on twice daily, immediate-release tacrolimus versus those maintained on Astagraf XL in the first two years post-transplant.